Preview Mode Links will not work in preview mode

This Week in Cardiology

Jul 8, 2022

On this week’s podcast, John Mandrola, MD discusses fish oil, America’s heart health, pharmacists and prescribing and statins This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I - Fish Oil

- New Biomarker Data Add to Concerns Over REDUCE-IT Trial

- Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskThe STRENGTH Randomized Clinical Trial

- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial

II - US Heart Health

- New AHA Checklist: Only 1 in 5 Adults Have Optimal Heart Health

- Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association

- Status of Cardiovascular Health in US Adults and Children Using the American Heart Association's New "Life's Essential 8" Metrics: Prevalence Estimates from the National Health and Nutrition Examination Survey (NHANES), 2013-2018

III - Pharmacist Prescribing

- Paxlovid Is Here: A Pharmacist's Prescribing Pearls

- Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations

IV - Statin Eligibility

- New European Guidelines ‘Drastically’ Reduce Statin Eligibility

- Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

- Time to Revisit Using 10-Year Risk to Guide Statin Therapy

- Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps

You May Also Like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact